Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 208

Avalyn waves through series B funds

Novo and Pivotal BioVenture Partners both invested as the lung disease therapy developer took its overall funding close to $100m.

Apr 29, 2020

Actym Therapeutics actions $34m series A

Boehringer Ingelheim Venture Fund co-led the cancer immunotherapy developer's series A round, which also featured Illumina Ventures.

Apr 29, 2020

LifeSprout bolts on series A funding

Medytox-backed restorative materials technology developer Lifesprout secured $28.5m in a round led by Redmile Group as it looks to move into regenerative medicine.

Apr 28, 2020

Compass points to $80m series B

Otsuka Pharmaceuticals's McQuade Center for Strategic Research and Development backed the psilocybin-based mental health drug developer through the round.

Apr 28, 2020

Corporates head to Rome for $50m series A

Repeatome drug developer Rome Therapeutics was incubated within GV, which took part in the series A round along with fellow corporate unit Partners Innovation Fund.

Apr 28, 2020

Oric ordains $120m initial public offering

Cancer therapy developer Oric, whose backers include Memorial Sloan, Taiho and Hartford HealthCare, floated at the top of its range in an expanded IPO.

Apr 27, 2020

Corporate venturing deal net: 20-24 April 2020

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Apr 24, 2020

Accent emphasises $63m series B round

GV, AbbVie Ventures and NS Investment have contributed to a series B round for the oncology drug developer, which has now raised a total of $103m.

Apr 24, 2020

HLB helps insert more funding into Immunomic

The HLB-led group owns nearly half of vaccine product developer Immunomic Therapeutics following a $61.3m commitment this year.

Apr 24, 2020

SwanBio swivels to $52m in series A

Partners Innovation Fund joined Syncona to provide $20m for the neurological disease drug developer's series A round, which is sized at up to $77m.

Apr 24, 2020

© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here